Send us a text

Jack Lu, Director of Corporate Development, of Ainos joins us on this week’s WTR Small-Cap Spotlight to discuss the therapeutic platform and Veldona clinical development. He reviews the effects of Veldona on the immune system and benefit seen in prior clinical trials. Jack focuses on the recently announced studies being conducted in Taiwan for the three priority indications of oral warts in HIV+ patients, Sjogren’s syndrome, and cat FCGS in animal health. We get a sense of timelines for potential data catalysts and outcome goals.